Jennifer N. Brudno, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Suite 3-3330
- Bethesda, Maryland 20892
- 240-858-3213
- jennifer.brudno@nih.gov
RESEARCH SUMMARY
Dr. Brudno researches the use of chimeric antigen receptor (CAR) T-cell therapy to treat cancers of the blood, including Non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia (ALL), and multiple myeloma. Her focus is in the development of phase I clinical trials. She is also interested in patient safety, particularly in optimizing patient safety for cellular immunotherapies.
Areas of Expertise
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Jennifer N. Brudno, M.D.
Clinical Trials
Research
Dr. Brudno conducts clinical trials to investigate new therapies for hematologic malignancies. Her focus is in the development and execution of clinical trials of chimeric antigen receptor (CAR) T-cell therapy.
Publications
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Chimeric antigen receptor T-cell therapies for lymphoma
Toxicities of chimeric antigen receptor T cells: recognition and management
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Discordant bone marrow involvement in non-Hodgkin lymphoma
Biography
Jennifer N. Brudno, M.D.
Dr. Brudno received her Bachelor of Arts from Princeton University and her M.D. from the Emory University School of Medicine. While in medical school, she participated in the NIH Clinical Research Training Program (CRTP), during which she worked with Dr. Neal Young in the National Heart, Lung, and Blood Institute. She completed her medical residency in internal medicine at the Johns Hopkins University School of Medicine. She then completed fellowship training in medical oncology and hematology through the National Cancer Institute and the National Heart, Lung, and Blood Institute. After fellowship training, she joined the research group of Dr. James Kochenderfer.
Dr. Brudno is board certified in internal medicine, hematology, and medical oncology.
